US 8,802,128 B2Granted

Steroid-containing sustained release intraocular implants and related methods

AssigneeAllergan, Inc.

InventorsMichael R. Robinson, Scott M. Whitcup

Life of this patent

Estimating the term…

Loading patent…

Abstract

Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.

Claims2

Dependent claims

A biodegradable intraocular implant comprising:

a combination of biodegradable poly(D,L,-lactide-co-glycolide) and poly(D,L,-lactide) polymers in a 1:2 ratio, respectively, and an alpha-2 adrenergic receptor agonist and a steroid in a 60:40 weight ratio of drug to polymer, wherein the alpha-2 adrenergic agonist and steroid are arranged in interleaved alternate layers;
wherein the alpha-2 adrenergic receptor agonist is selected from the group consisting of apraclonidine, clonidine, oxymetazoline, epinephrine, norepinephrine, dexmedetomidine, mivazerol, xylazine, medetomidine, and brimonidine;
and
wherein the steroid is selected from the group consisting of cortisone, prednisolone, fluorometholone, dexamethasone, medrysone, loteprednol, fluazacort, hydrocortisone, betamethasone, prednisone, methylprednisolone, triamcinolone hexacatonide, paramethasone acetate, triamcinolone acetonide, diflorasone, fluocinonide, and mixtures thereof.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 11/491,353Filed 21 Jul 2006 · continuation in part
Priority: 23 Jun 2006
Published: US 2007/0298073 A127 Dec 2007
Granted: 12 Aug 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 9/0051
Eye, e.g. artificial tears: ocular inserts or implants
A61K 31/498
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/573
Substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone: substituted in position 21, e.g. cortisone,…
A61K 31/58
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: containing heterocyclic rings, e.g. danazol,…